Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional studyBMJ MEDICINEIF102024-04-050OAAI
Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus TherapiesJOURNAL OF RHEUMATOLOGYIF3.42023-12-150OA
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017JAMA HEALTH FORUMIF11.32022-05-2712OA
Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological studyBMJ-BRITISH MEDICAL JOURNALIF42.72022-05-1017OAAI
Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated ApprovalJAMA NETWORK OPENIF9.72021-11-0918OAAI
Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer TherapeuticsJAMA NETWORK OPENIF9.72021-04-2032OAAI
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or CommitmentsJAMA NETWORK OPENIF9.72019-05-1014OAAI